Participated · Series B · Jun 2026

Ollin Biosciences, founded in 2023 and based in Austin, Texas, is advancing a pipeline of bispecific antibodies for retinal and orbital diseases. Its lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody discovered in collaboration with Innovent Biologics; in a 164-patient randomized head-to-head Phase 1b (JADE) study versus faricimab (Vabysmo®) OLN324 demonstrated faster and greater anatomic retinal drying and numerically greater vision gains. Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026 after completing regulatory discussions with the FDA and receiving EMA scientific advice. The company’s second program, OLN102, is a TSHR/IGF-1R bispecific antibody discovered with VelaVigo and is expected to enter clinical development in 2026 for thyroid eye disease and Graves’ disease. Ollin positions its candidates as potentially best-in-disease therapies and is using recent financing to fund registrational studies and further clinical development.

Participated · Series E · May 2026

Photonic pursues a distributed approach to quantum computing through its Entanglement First architecture, which combines silicon-based qubits with native photonic connectivity to enable scaling across existing telecom fiber infrastructure. The company positions this architecture as a path toward fault-tolerant, commercial-scale quantum systems that can interoperate with global cloud and telecom networks. Photonic is engaged in programs including Canada’s Quantum Champions Program and Stage B of DARPA’s Quantum Benchmarking Initiative. With the recent financing, Photonic has raised over $350 million USD to date and closed a round valuing the company at $2.0 billion USD post-money. The firm says it will use the new capital to advance platform development, deepen telecom and strategic partnerships, grow its team, and pursue near-term milestones. Investors supporting Photonic range from government development banks and national telecoms to multinational strategic and growth equity backers.

Participated · Series E · Apr 2026

Alloy Therapeutics combines proprietary AI/ML, real-world data, and wet-lab execution to provide integrated discovery and development services across multiple biologic modalities, including antibodies, bispecifics, genetic medicines, TCRms, cell therapies, and drug delivery. Since its 2017 founding, Alloy has partnered with over 200 organizations, generated more than 100 licensed therapeutic programs, and advanced 22 programs into clinical development, with two programs in Phase 3. The company has expanded beyond discovery into pharmacology, preclinical and clinical development services, and biologics manufacturing, positioning itself as a full-stack biotech infrastructure provider. Alloy operates a distributed model with centers of excellence across the U.S., Japan, the Middle East, and other emerging markets. Financially, the company just raised $40 million in a Series E at a $1.0 billion valuation to scale its services and accelerate its AI/ML and data capabilities.

Led · Series A · Feb 2026

Salma Health delivers end-to-end brain health care by uniting psychiatry, neurology, psychology, crisis services, and clinical research under one roof. Its specially equipped clinics offer treatments such as conventional and accelerated TMS, SAINT neuromodulation, esketamine therapy, psychotherapy, and pharmacotherapy, all personalized via rigorous clinical assessments. The company operates locations in San Diego, Orange County, Fremont, and Berkeley and intends to expand nationally. Complementing in-person care, Salma Health runs telehealth services and an FDA-regulated clinical trial platform that partners with pharmaceutical and medical-device firms. Central to its model is an AI-powered “Brain Health OS” that integrates clinical data to support precision diagnostics, outcome tracking, and care coordination. Deep patient profiling across neural, physiological, and digital markers generates a comprehensive dataset meant to drive predictive models and real-world evidence. By publishing outcomes and collaborating with health systems and regulators, Salma Health aims to set new clinical guidelines and advance personalized brain healthcare.

Participated · Equity · Feb 2026

Waymo develops and operates fully driverless robotaxis, offering on-demand rides across multiple U.S. metropolitan areas. Its fleet now delivers roughly 400,000 rides each week in six major cities, and the company more than tripled annual volume in 2025 to 15 million rides, surpassing 20 million lifetime trips. Having secured permits to charge for rides in California, Waymo has expanded from its original Phoenix deployment to San Francisco, Los Angeles, Austin, Atlanta, and Miami. The firm plans to enter more than a dozen additional international cities in 2026, including London and Tokyo, and is “laying the groundwork” for operations in 20+ further locations. Waymo positions itself as past the proof-of-concept stage and focused on global scale. The latest financing values the company at $126 billion and provides capital to grow vehicle supply, broaden geographic coverage, and reinforce operational infrastructure. Regulatory scrutiny remains, with U.S. safety agencies investigating recent incidents involving the fleet.